Abstract Body

Background

Opioid use disorder (OUD) is highly prevalent among persons with HIV-1 (PWH). While opioids modulate the immune system, their impact on the HIV-1 reservoir during antiretroviral therapy (ART) remains unclear. We leveraged the OPIS cohort to compare reservoir features, immune milieu, and HIV-specific responses in ART-treated PWH with or without OUD.

Methods

We studied PWH with OUD (OUD+, n=28; median age: 41.5, median ART duration: 2 years) or without OUD (OUD-, n=31; median age: 54, median ART duration: 17 years), all on ART with suppressed viral load (median: <20 copies/mL). Fentanyl was the predominant opioid, confirmed by urine testing. Reservoirs in CD4+ T cells were assessed using the Intact Proviral DNA Assay (IPDA) and cell-associated HIV-1 RNA quantified by digital PCR. Plasma inflammatory biomarkers were measured by Luminex/ELISA and summarized as a composite cytokine score. HIV-specific responses were evaluated by flow cytometric detection of activation-induced markers (AIM) following Gag stimulation.

Results

Median total and defective reservoir frequencies were significantly lower in OUD+ (372.7 and 257.7 copies per million cells) than OUD- (754.0 and 654.8 copies per million cells; p=0.0094 and p=0.0011), despite the shorter average ART duration received by OUD+. No significant differences were observed for the genome-intact reservoir between the OUD groups. Cell-associated HIV-1 TAR, LongLTR, and Pol transcripts were less frequent in OUD+, with reduced TAR/total proviral ratios indicating lower transcriptional activity (p=0.0048). OUD+ showed elevated plasma inflammatory markers (sCD25, IL-10, TNFα, IL-6, VCAM-1, sTNFRI/II, CCL2, IL-8, sCD14, IL-1β), confirmed by composite cytokine scoring (p=0.0001), which correlated with defective provirus levels. HIV-specific CD8+ T cell responses were diminished in OUD+, with fewer total (p=0.032) and central memory (p=0.016) AIM+ cells (CD69, CD40L, OX40, CD137, CD107a).

Conclusions

Fentanyl-associated OUD was linked to reduced and less transcriptionally active HIV-1 reservoirs, while amplifying systemic inflammation, and dampening HIV-specific immunity. These findings implicate opioids as key modulators of HIV persistence and immune function during ART, with implications for long-term immune control.